<DOC>
	<DOCNO>NCT00741221</DOCNO>
	<brief_summary>This trial evaluate efficacy safety pemetrexed bevacizumab combination patient pretreated , advance non small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Pemetrexed Plus Bevacizumab Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Pemetrexed effective well tolerate cytotoxic agent 2nd line treatment advance metastatic non small cell lung cancer ( NSCLC ) . Recently , phase III study 1st line treatment patient advance metastatic NSCLC show addition bevacizumab platinum-based regimen provide survival benefit . There patient NSCLC receive bevacizumab relapse 1st and/or 2nd line therapy . The evaluation bevacizumab plus chemotherapy patient justified . This study evaluate combination pemetrexed bevacizumab 2nd 3rd line treatment NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm , Unresectable locally advance ( stage IIIB ) metastatic ( stage IV ) nonsquamous NSCLC At least one two previous chemotherapy regimen advance metastatic NSCLC Measurable disease , define least 1 bidimensionally measurable lesion ≥ 20 X 10 mm . Age ≥ 18 year . Performance status ( WHO ) 02 . Life expectancy least 12 week . Adequate bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥ 100,000/mm3 , Hgb ≥ 11 g/dL ) , liver ( Bilirubin ≤ 1.5 Upper normal limit , SGOT/SGPT ≤ 2.5 Upper normal limit absence liver metastases ≤ 5 Upper normal limit presence liver metastasis ) , renal function ( Creatinine ≤ 1,5 Upper normal limit ) . Patients must able understand nature study give write informed consent Previous therapy pemetrexed Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer Pregnant lactate woman Any serious , uncontrolled comorbidity investigator 's judgment . Uncontrolled infection Any sustain chronic toxicity &gt; grade 2 accord NCI CTCAE ( version 3.0 ) Symptomatic neuropathy &gt; grade 2 accord NCI CTCAE ( version 3.0 ) Brain metastasis , except radiate asymptomatic Radiotherapy within previous 4 week Previous radiotherapy measurable lesion Proteinuria ≥ 500 mgr protein daily Hemoptysis &gt; 10 cc per event Clinically significant hematemesis Centrally locate lesion contact major vessel Pulmonary lesion cavitation Documented hemorrhagic diathesis coagulation disorder Cardiovascular disease ( class IIIV NYHA congestive heart failure , myocardial infarction within previous 4 month , unstable angina , LVEF &lt; normal , ventricular arrhythmia , uncontrolled hypertension ) Thrombotic event within previous 6 month Concurrent use aspirin &gt; 325 mgr daily , low molecular weight heparin therapeutic dose , warfarin acenocoumarol , nonsteroid antiinflammatory agent Concurrent treatment anticancer drug Major surgical procedure within previous 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>